Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects
- 10 August 2004
- journal article
- clinical trial
- Published by Springer Science and Business Media LLC in Psychopharmacology
- Vol. 179 (1), 303-309
- https://doi.org/10.1007/s00213-004-1982-8
Abstract
Some of the behavioral consequences of deficits in N-methyl-D-aspartate (NMDA) glutamate receptor function are thought to arise from the disinhibition of cortical glutamatergic circuitry. This study evaluated whether pretreatment with a drug that reduces glutamatergic activation, the group II metabotropic glutamate receptor (mGluR) agonist, LY354740, reduced the cognitive effects of the NMDA glutamate receptor antagonist, ketamine, in healthy human subjects. Nineteen healthy human subjects completed 3 test days during which LY354740 (matched placebo, 100 mg, 400 mg) was administered under double-blind conditions 4 h prior to the single-blind intravenous administration of saline and 5.7 h prior to ketamine administration (bolus of 0.26 mg/kg over 1 min, infusion of 0.65 mg/kg per hour for 100 min). Thus on each test day each subject received a single dose of LY354740 (or its matched placebo) and both saline and ketamine infusions. Ketamine impaired attention, working memory, and delayed recall. It also produced positive and negative symptoms, perceptual changes, and dysphoric mood. LY354740 did not have a significant effect on working memory on the placebo day; however, it produced a significant dose-related improvement in working memory during ketamine infusion. These data provide preliminary and suggestive evidence that LY354740 or other group II mGluR agonists might play a role in treating working memory impairment related to deficits in NMDA receptor function.Keywords
This publication has 42 references indexed in Scilit:
- Ketamine Increases Human Motor Cortex Excitability to Transcranial Magnetic StimulationThe Journal of Physiology, 2003
- LY354740, an mGlu2/3 Receptor Agonist as a Novel Approach to Treat Anxiety/StressStress, 2003
- Attenuation of Ketamine Effects by Nimodipine Pretreatment in Recovering Ethanol Dependent Men Psychopharmacologic Implications of the Interaction of NMDA and L-Type Calcium Channel AntagonistsNeuropsychopharmacology, 2001
- Psychosis: pathological activation of limbic thalamocortical circuits by psychomimetics and schizophrenia?Trends in Neurosciences, 2001
- Reversal of Phencyclidine Effects by a Group II Metabotropic Glutamate Receptor Agonist in RatsScience, 1998
- PHARMACOLOGY AND FUNCTIONS OF METABOTROPIC GLUTAMATE RECEPTORSAnnual Review of Pharmacology and Toxicology, 1997
- Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET)European Neuropsychopharmacology, 1997
- NMDA Receptor Function and Human Cognition: The Effects of Ketamine in Healthy VolunteersNeuropsychopharmacology, 1996
- Ketamine activates psychosis and alters limbic blood flow in schizophreniaNeuroReport, 1995
- The hopkins verbal learning test: Development of a new memory test with six equivalent formsThe Clinical Neuropsychologist, 1991